FDA D.I.S.C.O. Burst Edition: FDA approval of Lenvima (lenvatinib) in combination with Keytruda (pembrolizumab) for first-line treatment of adult patients with advanced renal cell carcinoma
0:00
3:30
Listen to a soundcast of the August 10, 2021 FDA approval of Lenvima (lenvatinib) in combination with Keytruda (pembrolizumab) for first-line treatment of adult patients with advanced renal cell carcinoma
Weitere Episoden von „FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)“
Verpasse keine Episode von “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)” und abonniere ihn in der kostenlosen GetPodcast App.